{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T12:21:00Z","timestamp":1782476460861,"version":"3.54.5"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Despite recent advances in screening and primary prevention, cervical cancer (CC) still represents the fourth leading cancer in terms of incidence and mortality among women. Immune checkpoint inhibitors (ICIs) have gradually emerged as a promising treatment option in the management of CC. However, their use is associated with immune-related adverse events (irAEs), which may occur up to several months after starting or ending therapy. Although irAEs can potentially affect any organs or systems, some sites, such as the nervous system, are seldom involved. We report on the case of a 54-year-old patient with HPV-related, recurrent and metastatic CC treated with cemiplimab. Following an initial favourable partial response, the treatment had to be interrupted due to the onset of immune-related pneumonitis. Subsequently, during steroid tapering, the patient developed myositis and myelitis requiring hospitalization. Further investigations including cerebrospinal fluid analysis, serologic testing, virological and microbiological studies, and radiological imaging excluded infectious, malignant and primary inflammatory neurological aetiologies, supporting the hypothesis of a delayed irAE. Despite immunosuppressive treatment with high-dose steroids and a course of plasmapheresis, the patient gained only partial clinical improvement, requiring a rehabilitation treatment in a specialised facility. The widespread use of immunotherapy in advanced-stage malignancies is expected to increase the incidence of irAEs, including rare and severe forms such as neurological events and those with delayed onset. Consequentially, structured and prolonged follow-up is essential for early identification and effective management of ICIs toxicities.<\/jats:p>","DOI":"10.3389\/fonc.2026.1796299","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T04:28:09Z","timestamp":1778732889000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case Report: Neurological immune-related adverse events with anti-PD-1 based immunotherapy in cervical cancer"],"prefix":"10.3389","volume":"16","author":[{"given":"Gaia","family":"Passarella","sequence":"first","affiliation":[{"name":"Medical Oncology Unit, Fondazione IRCCS San Gerardo dei Tintori","place":["Monza, Italy"]},{"name":"Medicine and Surgery Department, University of Brescia","place":["Brescia, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Vella","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit, Fondazione IRCCS San Gerardo dei Tintori","place":["Monza, Italy"]},{"name":"Medicine and Surgery Department, University of Milano Bicocca","place":["Monza, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erminia","family":"Ferrario","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit, Fondazione IRCCS San Gerardo dei Tintori","place":["Monza, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicoletta","family":"Provinciali","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit, Fondazione IRCCS San Gerardo dei Tintori","place":["Monza, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego Luigi","family":"Cortinovis","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit, Fondazione IRCCS San Gerardo dei Tintori","place":["Monza, Italy"]},{"name":"Medicine and Surgery Department, University of Milano Bicocca","place":["Monza, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Canova","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit, Fondazione IRCCS San Gerardo dei Tintori","place":["Monza, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jncc.2024.11.006","article-title":"Global burden of cervical cancer: current estimates, temporal trend and future projections based on the GLOBOCAN 2022","volume":"5","author":"Wu","year":"2024","journal-title":"J Natl Cancer Centre"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(22)00501-0","article-title":"Global estimates of incidence and mortality of cervical cancer in 2020: a baseline analysis of the WHO Global Cervical Cancer Elimination Initiative","volume":"11","author":"Singh","year":"2023","journal-title":"Lancet Glob Health"},{"key":"B3","unstructured":"I numeri del cancro in Italia 2023\n          \n          2023"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2023-004429","article-title":"ESGO\/ESTRO\/ESP guidelines for the management of patients with cervical cancer \u2013 update 2023","volume":"33","author":"Cibula","year":"2023","journal-title":"Int J Gynaecological Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/ijgo.12749","article-title":"Revised FIGO staging for carcinoma of the cervix uteri","volume":"145","author":"Bhatla","year":"2019","journal-title":"Int J Gynaecology Obstetrics"},{"key":"B6","doi-asserted-by":"publisher","first-page":"102555","DOI":"10.1136\/ijgc-2022-003801","article-title":"Proportions and incidence of locally advanced cervical cancer: a global systematic literature review","volume":"6","author":"Monk","year":"2023","journal-title":"Cancer Treatement Rev"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100579","article-title":"Recurrent or primary metastatic cervical cancer: current and future treatments","volume":"7","author":"Gennigens","year":"2022","journal-title":"ESMO Open"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.25962","article-title":"Race and nodal disease status are prognostic factors in patients with stage IVB cervical cancer","volume":"9","author":"Nishio","year":"2018","journal-title":"Oncotarget"},{"key":"B9","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1056\/NEJMra2404457","article-title":"Cervical cancer","volume":"392","author":"Krishnansu","year":"2025","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2112435","article-title":"Pembrolizumab for persistent, recurrent, or metastatic cervical cancer","volume":"385","author":"Colombo","year":"2021","journal-title":"New Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.04.009","article-title":"EMPOWER-Cervical 1\/GOG-3016\/ENGOT-cx9: Interim analysis of phase III trial of cemiplimab vs investigator\u2019s choice chemotherapy in recurrent\/metastatic cervical carcinoma","volume":"32","author":"Tewari","year":"2021","journal-title":"Ann Oncol"},{"key":"B12","unstructured":"Libtayo\u00ae (cemiplimab) approved by the European Commission as the first immunotherapy in second line recurrent or metastatic cervical cancer irrespective of PD-L1 expression level or tumour histology\n          \n          2022"},{"key":"B13","first-page":"175","volume-title":"Regime di rimborsabilit\u00e0 e prezzo, a seguito di nuove indicazioni terapeutiche, del medicinale per uso umano \u00abLibtayo\u00bb (Determina n. 309\/2024)","year":"2024"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumours: primary results from the DESTINY-PanTumor02 phase II trial","volume":"42","author":"Meric-Bernstam","year":"2023","journal-title":"J Clin Oncol"},{"key":"B15","unstructured":"FDA grants accelerated approval to tisotumab vedotin-tftv for recurrent or metastatic cervical cancer\n          \n          2021"},{"key":"B16","unstructured":"FDA approves tisotumab vedotin-tftv for recurrent or metastatic cervical cancer\n          \n          2024"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00056-5","article-title":"Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204\/GOG-3023\/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study","volume":"22","author":"Coleman","year":"2021","journal-title":"Lancet Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann Oncol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"100704","DOI":"10.1016\/j.iotech.2024.100704","article-title":"Updates in the pathogenesis and management of immune-related enterocolitis, hepatitis and cardiovascular toxicities","volume":"21","author":"McKenzie","year":"2024","journal-title":"Immunooncol Technol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1703481","article-title":"Immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25708","article-title":"Severe neurological toxicity of immune checkpoint inhibitors: Growing spectrum","volume":"87","author":"Dubey","year":"2020","journal-title":"Ann Neurol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2020.1738382","article-title":"Neurologic complications of immune checkpoint inhibitors","volume":"19","author":"Haugh","year":"2020","journal-title":"Expert Opin Drug Saf"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200314","article-title":"Clinical course of neurologic adverse events associated with immune checkpoint inhibitors: focus on chronic toxicities","volume":"11","author":"Rossi","year":"2024","journal-title":"Neurology: Neuroimmunolology Neuroinflamm"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-020-03687-2","article-title":"Neuroimmunological adverse events associated with immune checkpoint inhibitor: a retrospective, pharmacovigilance study using FAERS database","volume":"152","author":"Mikami","year":"2021","journal-title":"J Neuro-Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-006398","article-title":"Society for immunotherapy of cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology","volume":"11","author":"Naidoo","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B26","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/s1474-4422(23)00369-1","article-title":"Neurological adverse events of immune checkpoint inhibitors and the development of paraneoplastic neurological syndromes","volume":"23","author":"Farina","year":"2024","journal-title":"Lancet Neurol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3988\/jcn.2014.10.3.262","article-title":"Anti-Ma2 paraneoplastic encephalitis in association with recurrent cervical cancer","volume":"10","author":"Ney","year":"2014","journal-title":"J Clin Neurol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.91866","article-title":"Neuronal intermediate filament-positive paraneoplastic neurological syndrome in cervical squamous cell carcinoma","volume":"17","author":"Nguyen","year":"2025","journal-title":"Cureus"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1111\/jog.13619","article-title":"Anti\u2010Hu antibody\u2010mediated limbic encephalitis associated with cervical cancer: a case report","volume":"44","author":"Shin","year":"2018","journal-title":"J Obstetrics Gynaecology Res"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1212\/nxi.0000000000001014","article-title":"Updated diagnostic criteria for paraneoplastic neurologic syndromes","volume":"8","author":"Graus","year":"2021","journal-title":"Neurol Neuroimmunology Neuroinflamm"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.66.1389","article-title":"Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma","volume":"35","author":"Weber","year":"2017","journal-title":"J Clinal Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1453429","article-title":"Delayed immune-related adverse events profile associated with immune checkpoint inhibitors: a real-world analysis","volume":"15","author":"Yang","year":"2024","journal-title":"Front Pharmacol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.03.204","article-title":"Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma","volume":"32","author":"Owen","year":"2021","journal-title":"Ann Oncol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s40425-019-0645-6","article-title":"Delayed immune-related events (DIRE) after discontinuation of immunotherapy: diagnostic hazard of autoimmunity at a distance","volume":"7","author":"Couey","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.49.3981","article-title":"Adherence to CONSORT adverse event reporting guidelines in randomized clinical trials evaluating systemic cancer therapy: a systematic review","volume":"31","author":"P\u00e9ron","year":"2013","journal-title":"J Clin Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.52.2219","article-title":"Adverse event reporting in cancer clinical trial publications","volume":"32","author":"Sivendran","year":"2014","journal-title":"J Clin Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv182","article-title":"A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors","volume":"26","author":"Chen","year":"2015","journal-title":"Ann Oncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2112187","article-title":"Survival with cemiplimab in recurrent cervical cancer [Supplementary Appendix","volume":"386","author":"Tewari","year":"2022","journal-title":"N Engl J Med"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1796299\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T04:28:17Z","timestamp":1778732897000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1796299\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,14]]},"references-count":38,"alternative-id":["10.3389\/fonc.2026.1796299"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1796299","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,14]]},"article-number":"1796299"}}